Avandia Continues To Take Its Toll; GSK Restructuring Will Cut $1.5 Bil., Jobs
Executive Summary
Due in part to plummeting Avandia sales, GlaxoSmithKline will cut $1.5 billion in costs through a restructuring program targeting sales and manufacturing, the firm announced in a third quarter sales and earnings call Oct. 24
You may also be interested in...
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Merck Commercial Pilot Set To Fly Nationwide
Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said